 | | Vol. 12.24 – 2 July, 2021 |
| |
|
|
| Scientists used an all-human microtissue-engineered model of mineralized metastatic tissue combining human osteoprogenitor cells, 3D printing, and prostate cancer cells, to assess the effects of the antiandrogens, bicalutamide, and enzalutamide in a microenvironment.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors reported that monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, reciprocally interacted with androgen receptors (AR) in prostate cancer.
[Cancer Research] |
|
|
|
| Using single-cell RNA-sequencing, investigators identified and validated the in situ localization of three smooth muscle subtypes and two novel fibroblast subtypes in the human prostate.
[Journal of Pathology] |
|
|
|
| Through a kinome-centered CRISPR-Cas9 screen in CWR-R1 prostate cancer cells, scientists identified activated BRAF signaling as a determinant for enzalutamide resistance.
[Scientific Reports] |
|
|
|
| The authors investigated the effects of lenalidomide and pomalidomide on human prostate smooth muscle contraction, cytoskeletal organization, and growth-related functions in stromal cells.
[Life Sciences] |
|
|
|
| The rheological and mechanical properties of the prepared hydrogels were characterized, as well as in vitro release of the paclitaxel and in vitro activity on PC-3 prostate cancer cells.
[Journal of Biomedical Materials Research Part A] |
|
|
|
| Scientists investigated the impact of hydrophobic aromatic moieties in the peptide linker on prostate-specific membrane antigen affinity and in vitro performance.
[Journal of Biomolecular Structure and Dynamics] |
|
|
|
| Researchers showed that anti-androgen enzalutamide (ENZA) resistant prostate cancer cells used more mitochondrial metabolism leading to higher ox-phos as compared to the ENZA-sensitive cells and could become vulnerable to mitochondrial metabolism targeted therapies.
[Prostate] |
|
|
|
| Investigators confirmed that GAS5, a long noncoding RNA, could interact and suppress androgen receptor (AR) transactivation in CRPC C4-2 cells and revealed the important role of GAS5 in AR axis activity regulation and CRPC progression.
[Prostate] |
|
|
|
|
| The authors discuss relatively understudied aspects of estrogen receptor-α and androgen receptor activity in regulating protein synthesis as well as the potential of targeting mRNA translation in breast and prostate cancer.
[Cancers] |
|
|
|
|
| Cancer Targeted Technology received a milestone payment from Advanced Accelerator Applications International S.A. triggered by the upcoming clinical trials of investigational 18F-CTT1057, a diagnostic PET imaging agent for prostate cancer.
[Cancer Targeted Technology (Business Wire, Inc.)] |
|
|
|
|
|
|
|
| | University of Arizona – Tucson, Arizona, United States |
|
|
|
| | Exact Sciences – Indianapolis, Indiana, United States |
|
|
|
| | Mayo Clinic Health System – Rochester, Minnesota, United States |
|
|
|
| | Henry M Jackson Foundation for the Advancement of Military Medicine – Bethesda, Maryland, United States |
|
|
|
| | Institute of Oncology Research – Bellinzona, Switzerland |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
